Transverse Myelitis Clinical Trials

Find Transverse Myelitis Clinical Trials Near You

A Phase 3b, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adult Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 130
Healthy Volunteers: f
View:

• Diagnosis: NMOSD per 2015 international consensus criteria, and anti AQP4 antibody positive at Screening.

• Disease activity: ≥1 attack/relapse in the past 12 months.

• Disability: EDSS ≤7.

• Background therapy: If on IST and/or oral corticosteroids, participant should be on a stable maintenance regimen prior to Screening and plan to remain stable during the study unless relapse occurs. (Detailed agent specific duration/dose rules to be confirmed at screening.)

• Body weight: ≥40 kg.

• Vaccinated against meningococcal infections from serogroups A, C, W, Y (and B where available) within the 3 years prior to study intervention administration on Day 1.

Locations
Other Locations
China
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Chengdu
Research Site
NOT_YET_RECRUITING
Dongguan
Research Site
NOT_YET_RECRUITING
Jinan
Research Site
RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shijiazhuang
Research Site
NOT_YET_RECRUITING
Taiyuan
Research Site
NOT_YET_RECRUITING
Wenzhou
Research Site
NOT_YET_RECRUITING
Wuhan
Contact Information
Primary
Alexion Pharmaceuticals, Inc. (Sponsor)
clinicaltrials@alexion.com
1-855-752-2356
Time Frame
Start Date: 2026-07-20
Estimated Completion Date: 2028-09-19
Participants
Target number of participants: 19
Treatments
Experimental: Ravulizumab
Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by a weight-based maintenance treatment dose on Day 15 and every 8 weeks (q8w) thereafter for up to 50 weeks.
Sponsors
Leads: Alexion Pharmaceuticals, Inc.

This content was sourced from clinicaltrials.gov